ArticleInternational journal of oncology2023

VIM‑AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2‑mediated HMGCS1 mRNA stabilization.

Sheng-Jia Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.